Bridging Distances in PAH:
Bringing Best Practices to the People Through Telementoring

Faculty

KATHARINE CLAPHAM, MD

Assistant Professor in Cardiology, Associate Director Pulmonary Hypertension and Dyspnea Program, Director of Pulmonary Vascular Research, University of Utah
Salt Lake City, UT
Jean Marie Elwing, MD, FCCP

Professor of Medicine, Director of Pulmonary Hypertension Program
University of Cincinnati Pulmonary
Madeira, OH

Nicholas Kolaitis, MD MAS

Assistant Professor, Medicine
University of California San Francisco 
San Rafael, CA 

Program Overview

Pulmonary Arterial Hypertension (PAH) demands a personalized, multidisciplinary approach, encompassing specialized knowledge and novel treatments, a requisite often unfulfilled in remote regions due to significant gaps in access, expertise, and resources. The dearth of specialized PH centers and the ensuing reliance on general practitioners, compounded by geographical isolation from expansive medical communities, accentuates the urgency of integrating innovative treatments and the latest clinical trial data to enhance patient outcomes and refine risk management strategies.  Constrained resources in these areas further impede healthcare professionals' capacity to stay updated on groundbreaking guidelines, emergent therapies, and advancements in personalized, multidisciplinary care essential for managing PAH effectively. Complicating this scenario are prevailing technology and connectivity challenges, which curtail the adoption of telehealth initiatives and inhibit participation in telementoring programs — key conduits for disseminating knowledge on avant-garde therapies and clinical developments.  Consequently, a compelling need emerges for a strategic initiative, meticulously designed enable early detection, convey insights on current and novel treatments, disseminate pivotal clinical trial data, and elucidate strategies for individualized, multidisciplinary care to healthcare providers via telementoring. This initiative aspires to bridge the identified gaps, cultivate collaboration, and significantly elevate the standard of PAH management in underserved, resource-limited rural environments.   

Target Audience

This educational initiative is designed for pulmonologists, critical care, primary care physicians, nurse practitioners, physician assistants, surgeons, pharmacists, and nurses.

Learning Objectives

Upon completion of this activity, the participant should be able to:

  • SUMMARIZE best practices for decreasing the diagnostic interval in PAH.
  • EVALUATE the scientific evidence supporting the use of current and emerging therapeutics for PAH, discerning their current and potential roles in the treatment and management of this disease.
  • EXPLAIN how to implement newly refined risk assessment tools into practice even in remote settings.
  • INTEGRATE telehealth and telementoring practices, ensuring consistent remote access to specialized multidisciplinary teams for optimal care of PAH patients.

Educational Activities

Social Media Broadcasts
PAH Provider Tool Kit

SOCIAL MEDIA BROADCAST ONE

Credit Amount: 0.25
Credit Type: AMA
Release: August 26, 2024
Expiration: August 26, 2025

SOCIAL MEDIA BROADCAST THREE

Credit Amount: 0.25
Credit Type: AMA
Release: August 28, 2024
Expiration: August 28, 2025

SOCIAL MEDIA BROADCAST FIVE

Credit Amount: 0.25
Credit Type: AMA
Release: August 30, 2024
Expiration: August 30, 2025

SOCIAL MEDIA BROADCAST TWO

Credit Amount: 0.25
Credit Type: AMA
Release: August 27, 2024
Expiration: August 27, 2025

SOCIAL MEDIA BROADCAST FOUR

Credit Amount: 0.25
Credit Type: AMA
Release: August 29, 2024
Expiration: August 29, 2025

SOCIAL MEDIA BROADCAST SIX

Credit Amount: 0.25
Credit Type: AMA
Release: August 31, 2024
Expiration: August 31, 2025

Clinical Resource Center

Credit Amount: N/A
Release: August 26, 2024
Expiration: August 26, 2025

This activity is jointly provided by Global Education Group and Iridium Continuing Education.

SUPPORTER ACKNOWLEDGEMENT
This educational activity is supported by independent educational grants from Merck Sharp & Dohme LLC and Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson.

Maximum Credit Amount: 1.50
Credit Type: AMA
Release: August 26, 2024
Expiration: TBD